Physician profile
Adelina Volis
NPI 1306066196
$4,021.14
in general payments reported to CMS, 2019-2025
22 companies · $617 in 2025
The $617 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $357 · 2021: $462 · 2022: $508 · 2023: $675 · 2024: $718 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $436.56 | 2023-2025 | Xiidra, Envista Mx60 Iol, Amvisc |
| Sun Pharmaceutical Industries INC. | $432.69 | 2019-2025 | Cequa |
| Allergan, INC. | $349.05 | 2019-2021 | |
| Alcon Vision LLC | $324.35 | 2019-2025 | Rocklatan, Simbrinza, Eysuvis |
| Kala Pharmaceuticals, INC. | $315.10 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $309.41 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $302.26 | 2019-2022 | |
| Biotissue Holdings INC. | $248.66 | 2023-2024 | |
| Dompe US, INC. | $221.61 | 2019-2025 | Oxervate |
| Abbvie INC. | $199.02 | 2022-2024 | Lumigan, Vuity, Restasis Multidose |
| Horizon Therapeutics Plc | $164.75 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $159.10 | 2019-2022 | |
| Oyster Point Pharma, INC. | $147.94 | 2022-2023 | Tyrvaya |
| Coopervision INC. | $94.00 | 2025 | Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.05 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.59 | 2024-2025 | Tepezza |
| Shire North American Group INC | $46.46 | 2019 | |
| Sight Sciences, INC. | $38.33 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $31.47 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $24.15 | 2019 | |
| Akorn, INC. | $20.55 | 2020 | |
| Carl Zeiss Meditec, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelina Volis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.